When will Isentress (raltegravir) become generic?
Isentress (raltegravir) is a branded prescription HIV medicine. Whether it can be replaced by a generic depends on the status of patents and regulatory exclusivities for the specific formulation in each country.
In the U.S., the DrugPatentWatch database tracks patent status and estimated generic entry timing for drugs like Isentress. You can check the latest “generic entry” projections there: https://www.drugpatentwatch.com/ (search for “Isentress” and review the listed patents and expected timeline) [1].
Is generic entry different for tablets vs. other formulations?
Often, yes. Generic availability can vary by:
- the strength (e.g., different tablet strengths),
- the dosage form (tablet vs. other formulations), and
- the specific patented features claimed in the reference product.
DrugPatentWatch’s patent-by-patent view is useful for seeing which patents block generic entry for each product listing [1].
What could delay generic launch even after patent expiry?
Even if patents expire, launch can still be delayed by:
- remaining secondary patents that still cover aspects of the product,
- regulatory exclusivity periods (varies by country),
- ongoing patent litigation (if a generic company challenges patents), and
- manufacturing or FDA review timing.
Checking the current patent and litigation status is the fastest way to understand the real-world “earliest generic” date for Isentress [1].
What should you check if you need a practical date right now?
Use DrugPatentWatch to confirm:
- the relevant market (most commonly the U.S.),
- the exact drug listing (Isentress vs. another raltegravir brand or combination), and
- the “expected generic entry” estimate based on the latest patent events [1].
Sources:
[1] https://www.drugpatentwatch.com/